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Diastereoselective synthesis of P-chirogenic 
phosphoramidate prodrugs of nucleoside analogues 
(ProTides) via copper catalysed reaction.  
F. Pertusati,*
a
 and C. McGuigan
a 
The first copper-catalysed diastereoselective synthesis of P-
chiral phosphoramidate prodrugs (ProTides) is reported. 
This procedure allows the synthesis of diastereomeric-
enriched mixtures of ProTides. Application of this 
methodology to the asymmetric phosphorylation of purine 
and pyrimidine nucleoside analogues is presented. 
Nucleoside analogues (NAs) are an important class of molecules 
accounting for half of all antiviral drugs currently on the market 
and a number of anticancer agents that are widely used.1 All 
NAs require phosphorylation to be active. Unfortunately, many 
nucleoside analogues are not phosphorylated effectively in vivo, 
and thus their therapeutic potential is often quite limited. Using 
various approaches, the ionizable phosphate group can be 
masked by derivatization, thus generating prodrugs with 
increased lipophilicity.2 Among different prodrug strategies is 
the ProTide (pronucleotide) approach, which we introduced. The 
ProTide of a nucleoside phosphate is a phosphoramidate prodrug 
consisting of an amino acid ester, promoiety linked via a P-N 
bond to a nucleoside aryl phosphate. The ProTide technology 
was successfully and extensively applied to a wide variety of 
nucleoside phosphates.3 Several leading pharmaceutical 
companies have applied this technology for anti-viral and 
anticancer treatments. Gilead, has just launched on the market its 
anti-HCV ProTide, Sofosbuvir 1 (PSI-7977)4 whereas Nucana 
Biomed has taken to trial a gemcitabine ProTide, (NUC-1031, 
2)5 for patients with advanced solid tumours (Fig.1). Gilead has 
exploited this technology to create an advanced anti-HIV drug 
(GS 7340), an acyclic phosphonate analogue now in Phase III 
clinical trial.6 To further highlight the importance of 
phosphoramidates we note that this functional group is also 
present in important biological active molecules such as 
Phosmidosine7 and Agrocin 84.8 Two different synthetic 
strategies for the preparation of phosphoramidate prodrugs are 
commonly used.9 In the ﬁrst, tert-butyl magnesium chloride 
(tBuMgCl) is used as a base in the coupling reaction between a 
nucleoside and the phosphorochloridate bearing the desired 
promoieties. In the second approach, N-methyl imidazole (NMI) 
is used in place of tert-butyl magnesium chloride to promote the 
coupling. According to the two above-mentioned non-
stereoselective procedures, these prodrugs are generally 
prepared as 1:1 mixtures of diastereoisomers (Rp and Sp) 




Figure 1 Structure of important Phosphoroamidate prodrugs. 
 
Although stereoisomers have the same chemical structure they 
may exhibit differences in their pharmacology, toxicology, 
pharmacokinetics and metabolism. Up to now the 
phosphoramidate prodrugs cannot be easily prepared in the form 
of single diastereoisomers because of the lack of control of the 
stereochemistry at the phosphorus center during the synthesis. 
When it has been possible to separate the diastereoisomers, the 
biological activity has often been found dependent on the 
configuration on the phosphorus atom.10 For example Sp 
diastereoisomer of the GS7340 is 10 fold more potent against 
HIV than the Rp diastereoisomer10a Likewise, in HCV replicon 
assay Rp and Sp (more lipophilic) isomers of Sofosbuvir 
produced HCV activity with EC90 values of 7.5 M and 0.42 
M respectively, thus demonstrating approximately 18 fold 
difference in activity between the two diastereoisomers.10b This 
has lead Gilead to launch Sofosbuvir as a single diastereoisomer, 
at considerable difficulty and expense. To select the optimal 
isomer for clinical development, the two single diastereomers of 
1′-cyano-2′-C-methyl 4-aza-7,9-dideaza adenosine 
phosphoramidate, were profiled separately. The Sp isomer was 
found 6-fold more potent in the replicon assay and two times 
more efficient in the triphosphate formation in primary human 
hepatocytes.10c Finally, we were also able to demonstrate that 
phosphoramidates3a,b and phosphonoamidates3g diastereoisomers 
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Separation of diastereoisomers by crystallization proved to be an 
inefficient method to use especially at the end of a multistep 
synthesis such as in the case of Sofosbuvir (a crystal of pure 
diastereoisomer was necessary). Chromatographic separation is 
often impossible or in general is a very difficult task to achieve, 
where reverse-phase chromatography provided successful results 
only in few cases.11 A multistep approach to obtain ProTides in 
a diastereoselective fashion has also been developed by the 
Meier group, using a chiral auxiliary on the phosphoramidating 
reagent.12 This methodology still requires the synthesis and 
chromatographic purification of the chiral auxiliary, which is 
generally unstable and cannot readily be isolated or recycled. 
This method is also limited by modest yields and was only 
documented on a nucleoside substrate lacking competing 2’,3’-
hydroxyl groups. Ross and co-workers13 developed another 
synthetic method in which a diastereomerically pure 
phosphoramidating agent bearing a p-nitrophenyl or 
pentafluorophenyl as leaving groups was used. However, these 
reagents require purification by non-conventional supercritical 
fluid chromatography coupled with expensive chiral stationary 
phases.  According to our experience they are also unstable and 
decompose easily, with racemization of the phosphorus 
stereocenter occurring. These features make all these methods 
not very efficient and especially high-priced, time consuming 
and hard to scale up. We were in search of a catalytic 
methodology that will allow generation of the ProTide motif in a 
diastereisomeric fashion on a variety of biologically active 
molecules. Screening the literature, we came across with the 
work of Jones14 who developed a simple and effective method 
for the catalytic phosphorylation of alcohols using a 
chlorophosphate as phosphorylating agent in the presence of 
titanium catalyst. Since the common synthetic route toward 
ProTides implies the use of chlorophosphoroamidates9 
(analogous to Jones chlorophosphate) we decided to test the 
possibility to yield proTides with this approach having the 
intention next to tune the procedure to our advantage for the 
achievement of their diastereoselective synthesis. 2’-C-methyl-
6-O-methyl guanosine 3 and 4a were selected respectively as 
model nucleoside and as phosphate source.15 The synthesis of 
the resulting phosphoramidate 5a (Rp:Sp 1:1 mixture) which 
reached phase two clinical trials against HCV virus, has been 
previously reported.15 When we treated a THF solution of 3 with 
phosphochloridate 4a in the presence of 0.2 equivalent of 
titanium chloride at room temperature, 5a was obtained in low 
yield (12%) and without any diastereoselectivity as revealed by 
RP-HPLC analysis of the crude reaction mixture (Entry 1, Table 
1). Not at all satisfied with the result achieved we turned our 
attention to another Jones report16 on the phosphoryl transfer 
from chiral N-phosphoryl-5,5-diphenyl oxazolidinone to alcohol 
under copper (II) triflate catalysis. Since in these studies the 
phosphorylation was reported to be successful on two examples 
of nucleosides, we decided to evaluate the catalytic activity of 
Cu(OTf)2 in the synthesis of ProTide 5a. We reacted nucleoside 
3 with chloridate 4a in the presence of 0.2 equivalent of 
Cu(OTf)2, 1.5 equivalent of triethylamine and 0.1 equivalent of 
N,N1-ethylene bis-(benzaldimine) (BEN) as metal ligand in THF 
solution at rt. The desired product 5a was obtained after 12 
hours in 14% yield with a diastereomeric ratio 1:2.5 (RP-HPLC 
of crude mixture) in favour of the Sp isomer (Table 1, Entry 2). 
Intrigued by the first indication of diastereoselectivity we 
decided to investigate the importance of the presence of BEN as 
metal ligand. When BEN was excluded from the reaction 
mixture, ProTide 5a was obtained in 37 % yield and in a 1:7 
Rp:Sp diastereomeric ratio (RP-HPLC) (Scheme 1, Table 1, 
Entry 3). The yield was moderate but the diastereoisomeric 
excess was striking. Encouraged by these results we proceeded 
to further investigate the reaction conditions in order to find 
those optimal in terms of conversion and diastereoselectivity. A 
comprehensive screen of different parameters such as base, 
metal catalyst and solvent were thus performed (Table 1). 
 
Scheme 1. Synthesis of 5a under transition metal catalysed conditions. 
Table 1 Screening of different conditions. 
Entry MXn  (equiv) Base Solvent 
Conversion  
to  5a (%)a 
Rp/Sp 
d.r.a 
1 TiCl4 NEt3 THF 12 1:2.5 
2 c Cu(OTf)2 NEt3 THF 14 1:2.5 
3 Cu(OTf)2 NEt3 THF 37 (28)
b 1:6.2 
4 Cu(OTf)2 DBU THF 5 1:3.3 
5 Cu(OTf)2 DMAP THF 4 1.2.5 
6 Cu(OTf)2 NMI THF 1 1:1 
7 Cu(OTf)2 i-Pr2NH THF 34 1:3 
8 Cu(OTf)2 DIPEA THF 47 1:2.5 
9 Cu(OTf)2 - THF 0 - 
10 Yb(OTf)3 NEt3 THF 20 1:2 
11 Fe(OTf)3 NEt3 THF 15 1:1.7 
12 La(OTf)3 NEt3 THF 20 1.1:1 
13 AgOTf NEt3 THF 0 - 
14 Cu(OAc)2 H2O NEt3 THF 40 1:2.5 
15 CuI NEt3 THF 22 1:3.2 
16 Cu(OAc)2 
 H2O NEt3 THF 39 1:2 
17 Cu(SO4)2 H2O NEt3 THF 10 1:3.8 
18 CuOAc NEt3 THF 9 1:5 
19 - NEt3 THF 0 - 
20 Cu(OTf)2 NEt3 Ethylene glycol 0 - 
21 Cu(OTf)2 NEt3 1,4 dioxane 38 1:2.3 
22 Cu(OTf)2 NEt3 DME 14 1:5 
23 Cu(OTf)2 NEt3 CH3CN traces 1 
24 Cu(OTf)2 NEt3 Toluene traces 1:1.5 
25 Cu(OTf)2 NEt3 Pyridine NR - 
26 Cu(OTf)2 NEt3 CHCl3 traces 1:1.8 
27 Cu(OTf)2 NEt3 CH2Cl2 traces 1:1.6 
28 Cu(OTf)2 DIPEA DME 40 (35)
b 1:8 
Reaction conditions: 3 100 mg, MXn 0.2 equiv.; 4a 1 equiv.; solvent 10 
mL; Base 1.5 equivalent; ambient temperature, 12 h. a Determined by RP-
HPLC analysis of the crude mixture§. bIsolated yield; cN,N’-ethylenebis-
benzaldimine, (BEN) used as ligand (2 mol%).  
 
First, the nature of the base was probed (Table 1, Entries 3-9).  It 
can be observed that heterocyclic bases such as DBU, DMAP 
and NMI (Table 1, Entries 3-5), were ineffective in promoting 
the reaction and returned the desired compounds only in traces 
amount. Most of the other bases screened were efficient in terms 
of product yield, with the best results obtained with alkyl 
amines. When the reaction yield was considered, diisopropyl 
ethylamine (DIPEA) was the best amine yielding the 
phosphoroamidate in 47% yield even if with a poor 
diastereomeric ratio (Table 1, Entry 8). The best diastereomeric 
ratio was instead obtained with NEt3 in absence of ligand (Table 
1, Entry 3). It is interesting to note that no reaction occur in 
absence of the base (Table 1, Entry 9).  Because of these results 
triethylamine was selected as standard base for further 
screenings. Several metal salts were also evaluated (Table 1, 
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Entries 10-19).  Since the absence of metal ligand seems to be 
beneficial to the reaction we decided to assess all these metal 
salts under ligand-free conditions. We began our investigation 
by screening ytterbium, iron, and lanthanum triflates.  In all 
these cases 5a was formed in low yield and poor 
diastereoselectivity. Interestingly, the use of lanthanum triflate, 
in contrast with all other metal triflates, although in minimum 
amount, led to the inversion of the diastereoselectivity slightly in 
favour of Rp isomer. To evaluate the effect of the oxidation state 
of the copper as well as the effect of the counter ion on the 
outcome of the reaction we screened also other copper salts. 
Table 1 report some of the results obtained. Cu(OTf)2 was found 
to be the most suitable catalyst (Table 1, Entry 3). Increasing the 
catalyst loading to 1 equivalent did not affect either the yield or 
diastereoselectivity. Our control experiment without catalyst 
yielded no product 5a (Table 2, Entry 19). 
Finally, an assessment of the effect of the reaction medium on 
stereoselectivity and yield was performed (Table 1, Entries 20-
28). The use of ethereal solvents (except ethylene glycol) 
provided synthetically useful quantities of 5a maintaining a 
certain degree of diastereoselectivity. On the contrary, alkyl 
halide and aromatics solvents as well as pyridine and acetonitrile 
were less successful, yielding only traces of the desired 
phosphoramidate product 5a. Since in the base screening DIPEA 
was providing the best results in terms of yield we decided to 
assess DIPEA in combination with DME (Table 1, Entry 28). To 
our delight in this conditions phosphoramidate 5a was obtained 
in 40% yield and in a 1: 8.3 Rp/Sp d.r as assessed by RP-HPLC 
analysis of the crude reaction mixture (Figure 2). 5a (Rp/Sp dr 
1:8) was isolated by column chromatography in 35% yield, and 
its identity was confirmed by comparison with literature data.§  
 
Figure 2. A: HPLC traces of crude reaction mixture (Table 1, Entry 28). 
HPLC conditions: 90:10 H2O / CH3CN to 0:100 H2O / CH3CN in 30 min. 
Flow = 1 mL/min.; λ = 280 nm; B: 31PNMR (CD3OD, 202 MHz) of 5a (Rp : 
Sp d.r = 1.2:8.8); C: 31PNMR (CD3OD, 202 MHz) of 5a (Rp : Sp d.r. = 1:1). 
The optimum reaction time was found in all cases to be 8-12 h, 
with lower conversion being observed with shorter reaction 
times. Variation of reaction temperature did not improve our 
results. Optimal conditions were found with Cu(OTf)2 (0.2 
equiv.), DIPEA (1.5 equiv.) in DME at room temperature for 12 
h. The nature of the phosphorochloridate on the reaction 
outcome was then investigated (Scheme 2, Table 2).  
 
Scheme 2. Synthesis of phosphoramidates 5a-e under transition metal 
catalysed conditions. 
Table 2. Screening of phosphochloridates 4a-e 
Entry Cpds R R1 R2 
Conversion  
to 5a-e (%)a 
Rp/ Sp d.r.a 
1 4a CH3 Naph CH2tBu 40 (38)
b 1:8.3 
2 4b CH3 Ph CH2tBu 54 (27)
b 1:3 
3 4c CH3 Naph  Bn 72 (66)
b 1:6 
5 4d CH(CH3)2 Naph Bn 43 (35)
b 1:7.5 
4 4e CH3 Naph CH(CH3)2 18 (12)
b 1:5.4 
Reaction conditions: 3 100 mg, Cu(OTf)2 0.2 equiv.; 4a-e 1 equiv.; 
DME 20 mL; DIPEA 1.5 equivalent; r.t., 12 h. a Determined by RP-
HPLC of the crude mixture. bIsolated yield. 
 
From the data in Table 2 it appears immediately clear that bulky 
substituents on the phosphochloridate partner exert a certain 
effect on the stereoselectivity. In fact, high diastereoselectivity is 
obtained with neopentyloxy-L-alanyl phosphorochloridate 4a 
bearing a naphthyl group as aryloxy moiety, whereas a dramatic 
decrease in diastereoselectivity is observed with 4b bearing the 
less bulky phenyl group (Table 2, Entries 1 vs 2). Moreover, if 
the naphthyloxy phosphorochloridate 4c affords the 
phosphoroamidate 5b with a moderate diastereoisomeric ratio, 
the analogue phosphochloridate 4d bearing the more sterically 
hindered L-valinyl benzyl ester yielded 5d with an improved 
diastereoselectivity (Table 2 entries 3 vs 5). Moderate 
diastereoselectivity was also obtained for 5e starting from 
phosphochloridate 4e. Compounds 5a-e were all isolated by 
column chromatography on silica gel and fully characterized 
(see SI). Finally, it is noteworthy to highlight that in all the 
above reactions, the 5’ phosphoramidate is formed exclusively 
(1H-NMR and MS analysis) despite the fact that two OH groups 
are not protected. This constitutes a great synthetic advantage 
over other available methods since it avoids tedious protection-
deprotection steps typical of nucleoside chemistry. 
Having a successful protocol in hand its application to other 
nucleosides was investigate. Given our interest in the anticancer 
field we decided to apply this protocol to Clofarabine 6 and 
Nelarabine 7. The results are collected in Scheme 3. 
Phosphoroamidate 9a was obtained with an excellent conversion 
(70% isolated yield) and remarkably with opposite 
diastereoselectivity (d.r. = 3.5:1). 
 
Scheme 3. Scope of purine nucleosides, Protides 8a and 9a. bIsolated 
yield after column chromatography. 
 
To further expand the scope of the present methodology and 
especially because the recent approval of the anti-HCV drug 
Sofosbuvir (as single diastereoisomer)3 we decided to apply our 
protocol to pyrimidine nucleosides. 2’-Deoxy-2’-fluorouridine 
10 was selected as model nucleoside (Scheme 4).  
Disappointingly, when 10 was reacted with phosphochloridate 
4e under the optimized conditions, the phosphoroamidate 11e 
was recovered with a moderate conversion (38% by crude 
mixture HPLC analysis) with no remarkable diastereoselectivity 
(Table 3, Entry 1). This prompted us to investigate further the 

























6  R= NH2; R1= Cl; R2= F
4a
R
7  R= OCH3; R1= NH2; R2= OH
8a  R= NH2; R1= Cl; R2= F; d.r. = 1:1.5 (Rp : Sp)
9a  R= OCH3; R1= NH2; R2= OH; d.r. = 3.5:1
26%
70%
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Scheme 4. Synthesis of 11e under transition metal catalysed conditions. 
Table 3. Screening of reaction conditions. 
Reaction conditions: 10 100 mg, 4a 1 equiv.; Solvent 20 mL; a 
Determined by RP-HPLC of the crude mixture; bIsolated yield; c3’-O- 
regioisomer was observed. 
 
Cu(OTf)2 under a variety of conditions (solvent, base, etc.) was 
unproductive, returning the desired phosphoroamidate 11e in 
poor diastereoselective manner. Similar results were obtained 
screening other metal triflates (Table 3, Entries 2-4). We 
therefore returned our attention to other copper salts-complexes. 
The results are collected in Table 3. Copper (I) acetate proved to 
be the best catalyst in terms of diatereoselectivity returning 11e 
in 35% yield and 1:6.3 d.r (Table 3, Entry 7).§§ The use of 
Cu(CF3CO2)2 enhance the yield at the expense of the d.r (Table 
3, Entry 10). 
In conclusion we have developed a catalytic system capable of 
delivery the Sp diastereoisomer of phosphoramidate prodrug of 
nucleoside analogues in a good diastereomeric enhanced fashion 
even if still in moderate yield. Cu(OTf)2 proved to be the 
catalyst of choice for purine nucleosides whereas CuOAc 
appeared to be superior for pyrimidine nucleosides. This 
methodology can be successfully applied to a diverse set of 
nucleosides and phosphorochloridates. Further studies of this 
procedure will focus on improving the yield while retaining or 
further enhancing the diastereoselectivity. Investigations for 
elucidating the mechanism are currently underway in our 
laboratories. Jonah Wilkes is acknowledged for the synthesis of 
one ProTide.  
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